UK to report on transfusion-related vCJD (variant Creutzfeldt-Jakob disease) risk assessment:
This article was originally published in Clinica
Executive Summary
The UK is preparing to announce the results of an exercise to assess the risk of transmission of variant Creutzfeldt-Jakob disease (vCJD) via blood transfusion. It follows the confirmation in July of a second case of suspected infection. Precautionary measures were adopted in December 2003, following the first reported case. The problem surrounds the processing of UK plasma pooled from "many thousands" of UK donors. The results of the risk assessment exercise and any further precautionary measures will be announced at the end of a patient-notification exercise currently underway. Switzerland has announced that it is following the UK's lead in restricting the number of people who can be blood donors.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.